Severe inflammatory tinea capitis in a child receiving baricitinib therapy for alopecia areata

Rotaru, S.; Common, M.; Mahé, E.

doi:10.1016/j.annder.2023.02.001

Cited by 3 publications

(1 citation statement)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…18 Based on this review, we have summarized the latest reports of JAK inhibitor treatment for pediatric AA in the past 2 years (Table 1). 18,[20][21][22][23][24][25][26][27][28][29][30][31][32][33][34][35] Six cases involved the use of upadacitinib (selective JAK1 inhibitor) and abrocitinib (selective JAK1 inhibitor) in treating pediatric patients with AA, showing good tolerability. 18,[31][32][33][34][35] Upadacitinib and abrocitinib have been approved for severe AD in children aged ≥12 years.…”

Section: Discussionmentioning

confidence: 99%

Abrocitinib Improved Dupilumab-Resistant Severe Atopic Dermatitis with Comorbid Mild Alopecia Areata in a 12-Year-Old Boy: A Case Report with 1-Year Follow-Up

Liu,

Song,

Jin

2024

JAA

View full text Add to dashboard Cite

Atopic dermatitis (AD) may sometimes be comorbid with alopecia areata (AA). However, traditional treatments for AA show limited efficacy. New treatment options, such as dupilumab and Janus kinase inhibitors, have proven efficacy in addressing both AD and AA. This article highlights the challenging case of a 12-year-old boy experiencing severe refractory AD and comorbid AA treated with oral abrocitinib after dupilumab failure with 1-year follow-up. After 3 months of treatment, his skin manifestations improved and the hair completely regenerated. No adverse reactions were observed during the 1-year follow-up period. This case provides evidence of the efficacy and safety of using abrocitinib to treat pediatric patients with both AD and AA.

show abstract

Section: Discussionmentioning

confidence: 99%

Abrocitinib Improved Dupilumab-Resistant Severe Atopic Dermatitis with Comorbid Mild Alopecia Areata in a 12-Year-Old Boy: A Case Report with 1-Year Follow-Up

Liu,

Song,

Jin

2024

JAA

View full text Add to dashboard Cite

show abstract

Baricitinib

2023

Reactions Weekly

View full text Add to dashboard Cite

Kerion Celsi in infants and children—A narrative review 2010–2023

Chiriac,

Diaconeasa,

Voicu

et al. 2023

Mycoses

View full text Add to dashboard Cite

Kerion Celsi is an inflammatory, deep fungal infection of the scalp. It is rare in neonates but gets more common in children about 3 years and older. It represents with swelling, boggy lesions, pain, alopecia and purulent secretions. Secondary bacterial infection is not unusual after maceration. Extracutaneous manifestations include regional lymphadenopathy, fever and very rare fungemia. Id‐reactions can occur. Diagnosis is based on clinical suspicion, clinical examination and medical history. Diagnosis should be confirmed by microscopy, fungal culture and molecular procedures. The most common isolated fungal species are anthropophilic Trichophyton (T.) tonsurans and zoophilic Microsporum (M.) canis, while geophilic species and moulds rarely cause Kerion Celsi. Treatment is medical with systemic and topical antifungals supplemented by systemic antibiotics when necessary, while surgery needs to be avoided. Early and sufficient treatment prevents scarring alopecia. The most important differential diagnosis is bacterial skin and soft tissue infections.

show abstract

Severe inflammatory tinea capitis in a child receiving baricitinib therapy for alopecia areata

Cited by 3 publications

References 6 publications

Abrocitinib Improved Dupilumab-Resistant Severe Atopic Dermatitis with Comorbid Mild Alopecia Areata in a 12-Year-Old Boy: A Case Report with 1-Year Follow-Up

Abrocitinib Improved Dupilumab-Resistant Severe Atopic Dermatitis with Comorbid Mild Alopecia Areata in a 12-Year-Old Boy: A Case Report with 1-Year Follow-Up

Baricitinib

Kerion Celsi in infants and children—A narrative review 2010–2023

Contact Info

Product

Resources

About